CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Inclusion Criteria: * Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed * Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD\>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy. * Measurable disease by RECIST 1.1 * ECOG performance status of 0 or 1 * Adequate bone marrow, liver and kidney function * Negative pregnancy test for women of child bearing potential * Agreement to use effective methods of contraception per the protocol requirements Exclusion Criteria: * Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy * Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured * Active, known, clinically serious infections within the 14 days prior to first dose of investigational product * Use of systemic corticosteroids or other systemic immunosuppressive drugs * Active, known or suspected autoimmune disease * History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis * History of interstitial lung disease * History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.